TB-500 · DECODED
TB-500
Decoded · Grey Market · Thymosin Beta-4 Fragment
BY THE NUMBERS
HOW IT WORKS
A synthetic fragment of Thymosin Beta-4 (Tβ4). Proposed to sequester monomeric G-actin, modulating actin polymerization dynamics and promoting cell migration and angiogenesis. TB-500 is not identical to full Tβ4, and pharmacokinetic or mechanistic data from Tβ4 studies cannot be directly applied to this fragment. All evidence is preclinical.
WHERE IT CAME FROM
Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino acid protein that the body produces in abundance. Its primary known function is actin sequestration: it binds G-actin (the building-block form of actin) and regulates how actin assembles into the filaments that make up cell structure and enable cell movement. This actin-binding function underlies its observed effects on cell migration, wound healing, angiogenesis, and tissue repair. Tβ4 is one of the most abundant proteins inside cells and was studied for decades as a naturally occurring healing factor.
TB-500 is a synthetic fragment of Tβ4, specifically the acetylated 17-23 residue region of the full molecule (Ac-LKKTETQ), which is the sequence primarily responsible for actin binding. It was developed as a potentially more stable and bioavailable version of the active portion of the molecule. Research on TB-500 as a distinct compound is limited almost entirely to preclinical settings. The human cardiac studies that sometimes appear in discussions of this compound were done on the full Tβ4 molecule, not on TB-500. Those results do not automatically apply to the fragment. TB-500 is sold in the grey market and used primarily for soft tissue injury recovery, though the evidence for this specific application in humans does not exist.
THE STUDIES
WHAT THE STUDIES SHOW
ANIMAL DATA
- ▸Accelerated soft tissue healing in rodent models
- ▸Tendon and ligament repair signals in equine use
- ▸Angiogenesis and cell migration in preclinical models
- ▸Wound healing acceleration across multiple tissue types
EXTRAPOLATED (FROM TΒ4)
- ▸Full Tβ4 not acutely toxic in limited human cardiac safety studies
- ▸Actin binding mechanism is established for Tβ4, assumed for fragment
- ▸Fragment ≠ molecule: these data points are not equivalent
- ▸No direct human efficacy data for TB-500 fragment specifically
UNKNOWN
- ▸Effective dose range in humans
- ▸Whether fragment activity matches full molecule activity
- ▸Long-term safety at grey market doses
- ▸Whether soft tissue benefits in horses/rodents translate to humans
SIDE EFFECTS
REPORTED (ANECDOTAL)
- ▸Injection site reactions
- ▸Transient fatigue or lethargy (reported in some users)
- ▸Mild headache
- ▸No controlled trial safety data exists for TB-500 specifically
NOTABLE / MONITOR FOR
- ▸WADA banned (S0): prohibited for all athletes in competition
- ▸Grey market supply: no quality control for purity, sterility, or concentration
- ▸Confusion with full Tβ4: may receive mislabeled product
- ▸Theoretical concern: actin-binding and angiogenic effects could theoretically interact with healing pathways in ways that are not well understood at higher doses
- ▸No long-term safety data from controlled studies
REGULATORY STATUS
TB-500 was on the FDA's Category 2 prohibited list for 503A compounding. On April 15, 2026, the FDA removed TB-500 from that explicit prohibition as part of a review of 12 compounds. This removal does not mean TB-500 is approved or compoundable. The PCAC is scheduled to review TB-500 alongside six other compounds at the July 23–24, 2026 meeting to evaluate 503A eligibility. WADA prohibits TB-500 under the S0 category (non-approved substances), banning it regardless of regulatory decisions by individual drug agencies. There is no active pharmaceutical development program pursuing FDA approval for TB-500.
PROS & CONS
PROS
- +Mechanistically connected to a well-understood biological process (actin binding, cell migration)
- +Animal models show consistent healing signals across multiple tissue types
- +Equine medicine use provides observational data at scale
- +Full Tβ4 molecule has limited human safety data that is not alarming
- +Widely discussed in the grey market. Serious adverse events would likely have surfaced by now if they were common.
CONS
- −No completed human interventional trials for TB-500 as the specific compound
- −WADA banned: prohibited in competitive sport
- −Fragment ≠ full molecule: Tβ4 human data does not automatically apply
- −Grey market supply has no quality assurance
- −Animal-to-human translation in recovery peptides is historically poor
- −No regulatory pathway currently exists
DAILY PEPTIDE VERDICT
RANKING
TB-500's mechanism makes sense. Actin binding, cell migration, angiogenesis, and tissue repair are real biological processes, and the fragment captures the part of the Tβ4 molecule that drives them. The animal data is consistent. The equine use adds observational weight. The problem is the same one that applies to every grey market recovery compound: there are no controlled human trials. The Tβ4 human data that sometimes gets cited was done on a different molecule. Someone using TB-500 for tendon or ligament recovery is making a reasonable mechanistic bet, but they are doing it without the human clinical evidence that would justify confidence. The PCAC review in July 2026 will be worth watching. It will be the first formal regulatory assessment of whether the evidence warrants 503A compounding eligibility.
DISCLAIMER · EDUCATIONAL USE ONLY
This document is for educational and informational purposes only. TB-500 does not hold general FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.